- Home
- APLM vs ADXN Comparison
APLM vs ADXN Comparison
Compare APLM & ADXN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- APLM
- ADXN
- Stock Information
- Founded
- APLM 2016
- ADXN 2002
- Country
- APLM United States
- ADXN Switzerland
- Employees
- APLM N/A
- ADXN N/A
- Industry
- APLM Blank Checks
- ADXN Biotechnology: Pharmaceutical Preparations
- Sector
- APLM Finance
- ADXN Health Care
- Exchange
- APLM Nasdaq
- ADXN Nasdaq
- Market Cap
- APLM 6.9M
- ADXN 8.1M
- IPO Year
- APLM N/A
- ADXN N/A
- Fundamental
- Price
- APLM $6.14
- ADXN $9.38
- Analyst Decision
- APLM
- ADXN Strong Buy
- Analyst Count
- APLM 0
- ADXN 1
- Target Price
- APLM N/A
- ADXN $30.00
- AVG Volume (30 Days)
- APLM 7.8K
- ADXN 17.4K
- Earning Date
- APLM 08-13-2025
- ADXN 08-11-2025
- Dividend Yield
- APLM N/A
- ADXN N/A
- EPS Growth
- APLM N/A
- ADXN N/A
- EPS
- APLM N/A
- ADXN 0.10
- Revenue
- APLM $198,000.00
- ADXN $278,508.00
- Revenue This Year
- APLM $415.15
- ADXN $86.57
- Revenue Next Year
- APLM N/A
- ADXN N/A
- P/E Ratio
- APLM N/A
- ADXN $0.76
- Revenue Growth
- APLM N/A
- ADXN N/A
- 52 Week Low
- APLM $4.47
- ADXN $6.51
- 52 Week High
- APLM $35.98
- ADXN $13.27
- Technical
- Relative Strength Index (RSI)
- APLM 47.85
- ADXN 58.19
- Support Level
- APLM $6.21
- ADXN $8.50
- Resistance Level
- APLM $6.80
- ADXN $9.87
- Average True Range (ATR)
- APLM 0.52
- ADXN 0.78
- MACD
- APLM 0.00
- ADXN 0.05
- Stochastic Oscillator
- APLM 51.61
- ADXN 72.46
About APLM Apollomics Inc.
Apollomics Inc is an clinical-stage biopharmaceutical company focused on the discovery and development of oncology therapies with the potential to be combined with other treatment options to harness the immune system and target specific molecular pathways to inhibit cancer. The company programs include vebreltinib (APL-101), a potent, selective c-Met inhibitor for the treatment of non-small cell lung cancer and other tumors with c-Met alterations, and uproleselan (APL-106), a specific E-Selectin antagonist that has the potential to be used adjunctively with standard chemotherapy to treat acute myeloid leukemia.
About ADXN Addex Therapeutics Ltd
Addex Therapeutics Ltd is a clinical-stage biopharmaceutical company. The company is focused on the development and commercialization of an emerging class of novel orally available small-molecule drugs known as allosteric modulators. The company's geographical area of operations includes Switzerland and Europe. The Company operates in one segment, which is the discovery, development, and commercialization of small-molecule pharmaceutical products.